{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T15:55:12Z","timestamp":1793548512992,"version":"4.5.0"},"reference-count":33,"publisher":"Centers for Disease Control MMWR Office","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7401a1","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:13:23Z","timestamp":1736334803000},"page":"1-8","source":"Crossref","is-referenced-by-count":152,"title":["Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged \u226550 Years: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2024"],"prefix":"10.15585","volume":"74","author":[{"given":"Miwako","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Leidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Gierke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Accorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mini","family":"Kamboj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Kuchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Loehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam L.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R1","unstructured":"CDC. Active bacterial core surveillance (ABCs): ABCs bact facts interactive data dashboard. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. https:\/\/www.cdc.gov\/abcs\/bact-facts\/data-dashboard.html"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R2","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.15585\/mmwr.mm6846a5","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: updated recommendations of the Advisory Committee on Immunization Practices.","volume":"68","author":"Matanock","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R3","unstructured":"Kobayashi M. Summary of work group interpretation of EtR and policy options: PCV use in adults aged \u226550 years [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 23, 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/04-Kobayashi-Pneumococcal-508.pdf"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R4","unstructured":"Food and Drug Administration. Package insert: PREVNAR 20. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2024. https:\/\/www.fda.gov\/media\/149987\/download?attachment"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R5","unstructured":"Food and Drug Administration. Package insert: CAPVAXIVE. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2024. https:\/\/www.fda.gov\/media\/179426\/download?attachment"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R6","unstructured":"Food and Drug Administration. Package insert: VAXNEUVANCE. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2024. https:\/\/www.fda.gov\/media\/150819\/download?attachment"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R7","unstructured":"Food and Drug Administration. Package insert: PNEUMOVAX23. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2024. https:\/\/www.fda.gov\/media\/80547\/download"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.15585\/mmwr.mm7336a2","article-title":"Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024.","volume":"73","author":"Kobayashi","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R9","unstructured":"Food and Drug Administration. Package insert: Prevnar 13. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2024. https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert------Prevnar-13.pdf"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R10","unstructured":"Leidner AJ, Bletnitsky S. Summary of three economic analyses on the use of PCVs among 50\u201364 year old adults in the United States [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 23, 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/03-Leidner-Pneumococcal-508.pdf"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.15585\/mmwr.mm7104a1","article-title":"Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022.","volume":"71","author":"Kobayashi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7203a1","article-title":"Pneumococcal vaccine for adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023.","volume":"72","author":"Kobayashi","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R13","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/cid\/ciab375","article-title":"Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults.","volume":"73","author":"Isturiz","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R14","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/cid\/ciae316","article-title":"Prevalence, clinical severity, and serotype distribution of pneumococcal pneumonia among adults hospitalized with community-acquired pneumonia in Tennessee and Georgia, 2018\u20132022.","volume":"79","author":"Self","year":"2024","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R15","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.3390\/microorganisms11112813","article-title":"Epidemiology of pneumococcal pneumonia in Louisville, Kentucky, and its estimated burden of disease in the United States.","volume":"11","author":"Ramirez","year":"2023","journal-title":"Microorganisms"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R16","unstructured":"Kobayashi M. Evidence to recommendations framework: PCV20 use among adults who previously received PCV13 [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; October 19, 2022. https:\/\/stacks.cdc.gov\/view\/cdc\/122357"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R17","unstructured":"Kobayashi M. Summary of work group interpretations of EtR and policy option on PCV21 use in adults [Presentation slides]. Presented at the Advisory Committee on Immunization Practices meeting, Atlanta, GA; June 27, 2024. https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-06-26-28\/04-Pneumococcal-Kobayashi-508.pdf"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R18","doi-asserted-by":"publisher","first-page":"6422","DOI":"10.1016\/j.vaccine.2021.08.038","article-title":"Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged\u202f\u226550\u202fyears: a randomized phase III trial (PNEU-PATH).","volume":"39","author":"Song","year":"2021","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/QAD.0000000000003126","article-title":"Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV.","volume":"36","author":"Mohapi","year":"2022","journal-title":"AIDS"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.vaccine.2021.08.049","article-title":"A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE).","volume":"40","author":"Platt","year":"2022","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.1976581","article-title":"Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged \u226550 years: a randomized phase 3 trial (PNEU-FLU).","volume":"18","author":"Severance","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R22","unstructured":"Merck Sharp & Dohme. Safety, tolerability, and immunogenicity of V110 or V114 co-administered with a booster dose of mRNA-1273 in healthy adults (V110\u2013911). Rahway, NJ: Merck Sharp & Dohme; 2024. https:\/\/ClinicalTrials.gov\/show\/NCT05158140"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R23","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.vaccine.2021.12.067","article-title":"Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged \u226550\u00a0years: a randomized phase 3 trial (PNEU-TRUE).","volume":"40","author":"Simon","year":"2022","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/cid\/ciab990","article-title":"Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged \u226518 years.","volume":"75","author":"Essink","year":"2022","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R25","doi-asserted-by":"publisher","first-page":"e1489","DOI":"10.1093\/cid\/ciaa1045","article-title":"Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age.","volume":"73","author":"Hurley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R26","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.vaccine.2024.01.004","article-title":"A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults\u202f\u226560 years of age in Japan, South Korea, and Taiwan.","volume":"42","author":"Haranaka","year":"2024","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1473-3099(22)00526-6","article-title":"Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1\/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.","volume":"23","author":"Platt","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R28","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1473-3099(24)00344-X","article-title":"Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial.","volume":"24","author":"Platt","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R29","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/cid\/ciae383","article-title":"A phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-experienced adults 50 years of age or older (stride-6).","volume":"79","author":"Scott","year":"2024","journal-title":"Clin Infect Dis"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R30","unstructured":"Merck Sharp & Dohme. A phase 3 randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older. Rahway, NJ: Merck Sharp & Dohme; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05526716"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R31","unstructured":"Merck Sharp & Dohme. A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V116 in adults living with HIV. Rahway, NJ: Merck Sharp & Dohme; 2023. https:\/\/clinicaltrials.gov\/study\/NCT05393037"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R32","unstructured":"Merck Sharp & Dohme. Safety and immunogenicity of V116 in pneumococcal vaccine-na\u00efve adults 50 years of age or older (V116\u2013010, STRIDE-10). Rahway, NJ: Merck Sharp & Dohme; 2024. https:\/\/www.clinicaltrials.gov\/study\/NCT05569954?term=V116-010&rank=1"},{"key":"key-10.15585\/mmwr.mm7401a1-202501081139-R33","unstructured":"Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization. Atlanta, GA: US Department of Health and Human Services, CDC; 2024. www.cdc.gov\/vaccines\/hcp\/acip-recs\/general- recs\/downloads\/general-recs.pdf"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T11:41:21Z","timestamp":1736336481000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/74\/wr\/mm7401a1.htm?s_cid=mm7401a1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,9]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,9]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7401a1","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,9]]},"published":{"date-parts":[[2025,1,9]]}}}